1) In an updated analysis of the phase 2 DESTINY-Breast01 study, women with HER2-positive metastatic breast cancer ADC trastuzumab deruxtecan (Enhertu) continued to demonstrate favorable data, including a median progression-free survival of
a) 9.4 months
b) 13.4 months
c) 19.4 months
d) 23.4 months
The Answer is C. At this SABCS 2020, the investigators had gathered an additional 9.4 months of follow-up data from the cohort of heavily pretreated patients (n=134) previously exposed to ado-trastuzumab emtansine (T-DM1).
2) Analysis of the ADAPT Trial showed that many patients with with HR+/HER2- early breast cancer can be treated by endocrine therapy alone without adjuvant chemotherapy. Researchers the following patients meet criteria EXCEPT those with:
a) 0 to 2 involved lymph nodes and a recurrence score of 0 to 11
b) 0 to 3 involved lymph nodes and a recurrence score of 0 to 11
c) 0 to 2 involved lymph nodes and a recurrence score of 12 to 25, in whom an endocrine response is observed after short preoperative endocrine therapy.
d) 0 to 3 involved lymph nodes and a recurrence score of 12 to 25 who responded to preoperative endocrine therapy
The Answer is D. Patients with 3 involved lymph nodes and a recurrence score of 12 to 25 who responded to preoperative endocrine therapy had a lower 5-year distant DFS. However, overall, endocrine therapy response should be considered along with the recurrence score when deciding whether adjuvant chemotherapy is necessary HR+/HER2 early breast cancer.
3) Preliminary data from a phase 1b trial found that the combination of trastuzumab deruxtecan, a HER2-directed ADC and nivolumab, an immune checkpoint inhibitor, caused an increase in interstitial lung disease or pneumonitis adverse events than the control arm.
The Answer is B. The combination was well tolerated in patients with HER2-positive or HER2-low metastatic breast cancer, providing the first data showing that trastuzumab deruxtecan may be safely combined with an immunotherapy agent, at therapeutic doses of both agents and for a meaningful treatment duration.
4) What Phase 3 Trial presented data on abemaciclib combined with endocrine therapy compared to endocrine therapy alone, confirming and improving the statistically significant benefit in invasive disease-free survival of high-risk, node-positive, early-stage, HER+ and HER2- breast cancer:
The Answer is C. Patients who received abemaciclib with endocrine therapy had a 28.7% reduction in the risk of developing invasive disease. There was also a 31.3% reduction in developing metastatic disease. In patients whose tumors stained at least 20% for Ki-67, there was a reduction in the IDFS of 30.9%.